Kalvista Pharmaceuticals Stock Today
| KALV Stock | USD 11.89 0.11 0.92% |
PerformanceGood
| Odds Of DistressLow
|
Kalvista Pharmaceuticals is selling for under 11.89 as of the 23rd of March 2025; that is 0.92 percent decrease since the beginning of the trading day. The stock's lowest day price was 11.83. Kalvista Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of April 2015 | Category Healthcare | Classification Health Care |
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks KVD824, an oral product candidate for the treatment of HAE and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company has 49.72 M outstanding shares of which 5.83 M shares are now shorted by private and institutional investors with about 12.75 trading days to cover. More on Kalvista Pharmaceuticals
Moving against Kalvista Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Kalvista Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chief President | Benjamin Palleiko | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsKalvista Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Kalvista Pharmaceuticals' financial leverage. It provides some insight into what part of Kalvista Pharmaceuticals' total assets is financed by creditors.
| |||||
Kalvista Pharmaceuticals (KALV) is traded on NASDAQ Exchange in USA. It is located in 55 Cambridge Parkway, Cambridge, MA, United States, 02142 and employs 150 people. Kalvista Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 591.12 M. Kalvista Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 49.72 M outstanding shares of which 5.83 M shares are now shorted by private and institutional investors with about 12.75 trading days to cover.
Kalvista Pharmaceuticals currently holds about 142.08 M in cash with (89.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78.
Check Kalvista Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Kalvista Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kalvista Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kalvista Pharmaceuticals. Please pay attention to any change in the institutional holdings of Kalvista Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Kalvista Ownership Details
Kalvista Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Octagon Capital Advisors Lp | 2024-12-31 | 1.4 M | |
| Woodline Partners Lp | 2024-12-31 | 1.3 M | |
| Stempoint Capital Lp | 2024-12-31 | 992.8 K | |
| Emerald Advisers, Llc | 2024-12-31 | 836 K | |
| Geode Capital Management, Llc | 2024-12-31 | 822.4 K | |
| Dafna Capital Management Llc | 2024-12-31 | 811.7 K | |
| Schroder Investment Management Group | 2024-12-31 | 805.4 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 696 K | |
| Silverarc Capital Management, Llc | 2024-12-31 | 612.2 K | |
| Vr Adviser, Llc | 2024-12-31 | 6.2 M | |
| Suvretta Capital Management, Llc | 2024-12-31 | 4.9 M |
Kalvista Pharmaceuticals Historical Income Statement
Kalvista Stock Against Markets
Kalvista Pharmaceuticals Corporate Management
| Jarrod Aldom | Vice Communications | Profile | |
| Nicole Sweeny | Chief Officer | Profile | |
| Ryan Baker | Head Relations | Profile | |
| Brian Piekos | Chief Officer | Profile | |
| John McKune | VP Fin | Profile | |
| Thomas MBA | CEO Director | Profile |
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.